gelteq.com (GELS) Price to Earnings Ratio

Corporate emblem and logo of Gelteq (GELS)

This chart illustrates the P/E dynamics for Gelteq Limited (GELS), which generates revenue by licensing gel-based drug delivery systems. The business is based on innovative drug delivery methods for the B2B sector, targeting individuals with swallowing difficulties, where the indicator stands at -0.80. Operational efficiency is maintained through the optimization of raw material logistics and the establishment of warehouse reserves.

Gelteq Limited Inc (GELS) Price to Earnings Ratio: for the period 10/30/2024 - 11/13/2026

Comprehensive metric breakdowns and analytics for Gelteq Ltd (GELS)

- price and consensus price forecast:
Stock Price Gelteq Limited Inc|GELS - Price Target Chart
- market capitalization details:
Market Value Gelteq Limited|GELS - Enterprise Value
- book capitalization information:
Net Assets per Share Gelteq|GELS - Company Net Assets|Market Capitalization to Net Assets gelteq.com|GELS - Company Total Assets
- debt and solvency information:
Debt to Capital Gelteq Limited|GELS - Long-Term Debt to Capital|Short-Term Debt to Capital Ratio Gelteq Limited Inc|GELS - Company Total Debt|Debt to Net Assets Ratio Gelteq Limited|GELS - Company Long-Term Debt|Current Liabilities Gelteq|Intermediate Coverage Ratio gelteq.com
- earnings and market multiples details:
GELS - Net Profit|Projected Future Earnings Gelteq Limited|GELS - Price to Earnings Ratio|Future Price to Earnings Multiple Gelteq Limited Inc|GELS - Price/Earnings to Growth Ratio|Enterprise Value to EBITDA Ratio Gelteq Limited|GELS - Operating profit EBITDA|Net earnings per share (EPS TTM) Gelteq|GELS - Net earnings per share (EPS TTM)|Net earnings per share growth for the trailing year gelteq.com|GELS - Earnings growth in current year|Expected net earnings per share growth next year Gelteq Limited
General company analysis:gelteq.com - GELS
Original product of gelteq.com

This ratio reflects the market value of the business relative to its net income, determining the extent to which investors are overpaying per unit of earnings. A P/E analysis based on the company's financial statements allows for an assessment of capital density and order liquidity, which is critical for Gelteq Limited (GELS), as its gel technology licensing model ensures profit scalability without capital expenditures for production.

Analysis of competing companies

P/E Multiple vrtx.com|Price to Earnings Ratio Alnylam (ALNY)|Price to Earnings Ratio INSM (Insmed Inc.)|P/E Multiple UTHR (United Therapeutics Corp.)|Business Payback Period BioMarin Corp (BMRN)|BBIO: Price to Earnings Ratio|Market Cap to Net Income BGM|COGT: P/E Multiple|Market Cap to Earnings Xeris Biopharma Holdings, Inc. (XERS)|KROS (Keros Pharma) - P/E Multiple|Price to Earnings Multiple ARCT (Arcturus Corp)|Price to Earnings Ratio ETON (Eton Pharmaceuticals)|KMDA (kamada.com) - Company Value to Net Income|Price to Earnings Ratio Fulcrum Therapeutics, Inc. FULC|ABEO (Abeona Therapeutics, Inc.) - Market Cap to Net Income|Mereo BioPharma Group PLC - P/E Multiple|Company Value to Net Income PLX (Protalix BioTherapeutics, Inc)|PLRX: P/E Multiple|appliedtherapeutics.com (APLT) - P/E Multiple|Price to Earnings Ratio Rein Therapeutics|AYTU: Company Value to Net Income|Price to Earnings Ratio Chemomab Therapeutics (CMMB)|Price to Earnings Ratio srxhealth.com SRXH|P/E Multiple PLRZ (Polyrizon)|P/E Multiple Aeterna Zentaris Inc AEZS|Cyclo Therapeutics, Inc. - P/E Multiple|Market Cap to Net Income Ratio Inozyme Pharma, Inc. (INZY)|RPHM: P/E Multiple|Market Cap to Earnings COSCIENS Bio (CSCI)